In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the National Health Service (NHS) in England. 10 July 2024
Pharmaceutical
Shares in Spanish plasma-based medicines producer Grifols have risen by more than 10% over a three-day period. 10 July 2024
Pharmaceutical
The European authorities have granted marketing authorization for Livmarli (maralixibat), for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients from the age of three months. 10 July 2024
Biotechnology
USA-based drug conjugates (ADCs) developer Sutro Biopharma
has appointed Barbara Leyman, as chief business development officer, effective July 8, 2024. 10 July 2024
Pharmaceutical
A new report from the USA's Federal Trade Commission (FTC) underlines how the agency regards middlemen as having the potential to inflate drug prices. 10 July 2024
Biotechnology
Immunic, a US biotech developing a pipeline of orally-administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has appointed experienced biopharma executive Jason Tardio as chief operating officer and president. 9 July 2024
Pharmaceutical
During a speech on Tuesday, the UK’s new Secretary of State for Health and Social Care, Wes Streeting, said that he plans to boost the economy through the life sciences sector. 9 July 2024
Biotechnology
Shares of Dutch gene therapy company uniQure were up more than 50% at $5.68, after the company released positive early clinical results for its Huntington’s disease candidate. 9 July 2024
Pharmaceutical
Anticipation had been building for many weeks, but when the UK’s general election finally took place on 4 July, the outcome felt entirely inevitable. 9 July 2024
Pharmaceutical
UK-based liquid medicines maker Rosemont Pharmaceuticals says it has acquired Sabal Therapeutics along with its affiliates. 9 July 2024
Pharmaceutical
US pharma giant Pfizer is launching the process to identify a successor for Mikael Dolsten. 9 July 2024
Biotechnology
German biotech start-up SciRhom today revealed the closing of a 63 million euros ($70 million) Series A financing round. 9 July 2024
Biotechnology
Stalicla, a privately-held Swiss biotech developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders such as autism spectrum disorder, has named Purnanand Sarma as chair of its board of directors. 9 July 2024
Biotechnology
US biotech Moderna and Japan’s Mitsubishi Tanabe Pharma have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax. 9 July 2024
Biotechnology
French immuno-oncology company ImCheck Therapeutics has appointed Stephan Braun as chief medical officer. 9 July 2024
Pharmaceutical
While investors await the outcome of a head-to-head trial featuring GLP-1 heavyweights semaglutide and tirzepatide, a large retrospective observational study points to a likely winner. 9 July 2024
Biotechnology
Boston, USA-based clinical-stage biopharma company HilleVax saw its shares plummet more than 88% to $1.64 by lose of trading on Monday as it pulled the plug on its lead vaccine candidate in infants. 9 July 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics today announced the appointment of Simon Jones to the posts of chief financial (CFO) and chief operating officer (COO) of the company. 9 July 2024
Pharmaceutical
UK-based MedPharm, an Ampersand Capital Partners portfolio company, and the US firm Tergus Pharma, a Great Point Partners portfolio company, have jointly announced they are merging. 9 July 2024
Pharmaceutical
California’s IDEAYA Biosciences (Nasdaq: IDYA), a precision medicine oncology firm, has announced promising Phase II data for IDE397, lifting shares in the firm by around 15%. 9 July 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze